Literature DB >> 19254170

Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis.

Jean-Nicolas Tournier1, Robert G Ulrich, Anne Quesnel-Hellmann, Mansour Mohamadzadeh, Bradley G Stiles.   

Abstract

Bacillus anthracis is the causative agent of anthrax, a disease that plagues both humans and various animal species. Effective vaccines are available, but those approved for human use are crude culture supernatants that require multiple injections and a yearly boost. Many experts agree that it is now time for the next generation of human vaccines against anthrax. Accordingly, this review will succinctly focus upon: pathogenesis of B. anthracis, with particular emphasis upon the immune system; the pertinent biophysical nature of protective antigen, which includes how the protein toxin component affords protection as a vaccine target; alternative methods for improving protective antigen as an immunogen; and additional B. anthracis antigens that might further sustain protective titers in humans. In addition to a better understanding of the disease process elicited by B. anthracis, which will logically lead to better vaccines (and therapeutics), there also needs to be the same level of open-mindedness applied to the politics of anthrax.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19254170     DOI: 10.1586/14787210.7.2.219

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  20 in total

1.  Anthrax toxin targeting of myeloid cells through the CMG2 receptor is essential for establishment of Bacillus anthracis infections in mice.

Authors:  Shihui Liu; Sharmina Miller-Randolph; Devorah Crown; Mahtab Moayeri; Inka Sastalla; Shu Okugawa; Stephen H Leppla
Journal:  Cell Host Microbe       Date:  2010-11-18       Impact factor: 21.023

Review 2.  Anthrax lethal and edema toxins in anthrax pathogenesis.

Authors:  Shihui Liu; Mahtab Moayeri; Stephen H Leppla
Journal:  Trends Microbiol       Date:  2014-03-27       Impact factor: 17.079

3.  Revisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for Anthrax.

Authors:  Itai Glinert; Elad Bar-David; Assa Sittner; Shay Weiss; Josef Schlomovitz; Amir Ben-Shmuel; Adva Mechaly; Zeev Altboum; David Kobiler; Haim Levy
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

4.  Amphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigen.

Authors:  L K Petersen; Y Phanse; A E Ramer-Tait; M J Wannemuehler; B Narasimhan
Journal:  Mol Pharm       Date:  2012-03-20       Impact factor: 4.939

5.  Differential role of the interleukin-17 axis and neutrophils in resolution of inhalational anthrax.

Authors:  Kévin Garraud; Aurélie Cleret; Jacques Mathieu; Daniel Fiole; Yves Gauthier; Anne Quesnel-Hellmann; Jean-Nicolas Tournier
Journal:  Infect Immun       Date:  2011-10-24       Impact factor: 3.441

6.  Production and cell surface display of recombinant anthrax protective antigen on the surface layer of attenuated Bacillus anthracis.

Authors:  Yan-chun Wang; Sheng-ling Yuan; Hao-xia Tao; Ling-chun Wang; Zhao-shan Zhang; Chun-jie Liu
Journal:  World J Microbiol Biotechnol       Date:  2014-12-12       Impact factor: 3.312

7.  Identifying experimental surrogates for Bacillus anthracis spores: a review.

Authors:  David L Greenberg; Joseph D Busch; Paul Keim; David M Wagner
Journal:  Investig Genet       Date:  2010-09-01

8.  Anthrax SET protein: a potential virulence determinant that epigenetically represses NF-κB activation in infected macrophages.

Authors:  Shiraz Mujtaba; Benjamin Y Winer; Anbalagan Jaganathan; Jigneshkumar Patel; Miriam Sgobba; Raymond Schuch; Yogesh K Gupta; Shozeb Haider; Rong Wang; Vincent A Fischetti
Journal:  J Biol Chem       Date:  2013-05-29       Impact factor: 5.157

Review 9.  Anthrax vaccination strategies.

Authors:  Robert J Cybulski; Patrick Sanz; Alison D O'Brien
Journal:  Mol Aspects Med       Date:  2009-09-01

Review 10.  Bacillus anthracis edema factor substrate specificity: evidence for new modes of action.

Authors:  Martin Göttle; Stefan Dove; Roland Seifert
Journal:  Toxins (Basel)       Date:  2012-07-06       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.